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Dementia, including Alzheimer’s disease (AD), is a major disorder, leading to several ocular manifestations amongst the elderly
population. *ese visual disorders may be due to retinal nerve degenerative changes, including nerve ﬁbre layer thinning,
degeneration of retinal ganglion cells, and changes to vascular parameters. *ere is no cure for Alzheimer’s, but medicines can
slow down the development of many of the classic symptoms, such as loss of memory and communication skills, mood swings,
and depression. *e disease diagnosis is diﬃcult, and it is only possible through PETscans of the brain, detecting evidence of the
accumulation of amyloid and tau. PET is expensive and invasive, requiring the injection of radioactive tracers, which bind with
these proteins and glow during scanning. Recently, scientists developed promising eye-scan techniques that may detect Alz-
heimer’s disease at its earliest stage, before major symptoms appear, leading to improvedmanagement of the disease symptoms. In
this review, we are discussing the visual abnormalities of Alzheimer’s and other neurodegenerative diseases, focused on ocular
functional-visual-structural biomarkers, retinal pathology, and potential novel diagnostic tools.
1. Introduction
AD is a degenerative disorder of the nervous system,
eventually aﬀecting over 10% of individuals aged 65 or over.
It is the ﬁfth-leading cause of death among people older
than 65 years and a major cause of disability and poor
health [1–4]. According to the World Alzheimer Report of
2016, it is estimated that 47 million people suﬀer from
dementia worldwide, and this number could increase to
more than 131 million by 2050, as populations age [5]. Life
expectancy has increased dramatically over the past century
across the globe and consequently has been detected an
increase in the observed prevalence of chronic diseases
among the elderly people.
While the optical examination sector appears extremely
interesting for the development of a novel noninvasive di-
agnostic tool [6], genome-wide association studies have
identiﬁed more than 20 AD risk genes [7–10], but the exact
mechanism through which these genes are associated with
AD remains unknown [11–13]. More promising are the
studies on amyloid precursor protein (APP), presenilin 1
(PSEN1), and presenilin 2 (PSEN2) mutations, identifying
them as important factors of autosomal-dominant early-
onset AD and FAD [14].
As of 2018, there is no modifying therapy for AD [15],
and only two families of medications are approved as pal-
liatives for AD symptoms: the cholinesterase inhibitors and
the N-methyl-D-aspartate receptor (NMDAR) antagonists,
while various new drugs are under clinical trials evaluations,
among them the promising new family of secretase in-
hibitors [16–18].
Even though many preclinical and clinical trials on AD
drugs are underway, it is becoming obvious that the concept
of the simplistic therapy of one compound against one target
is failing, due to the complex pathophysiology of the disease,
and future treatment will be based on drug combinations to
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intensify the results [19]. In any case, the onset of Alz-
heimer’s disease cannot yet be stopped or reversed but might
be manageable.
Diagnosis of the disease is diﬃcult and frequently is
subjective. *ere is no single diagnostic test and specialists
are using various methods, including physical examina-
tion and brain scans, such as computed tomography (CT),
magnetic resonance imaging (MRI), or positron emission
tomography (PET), to rule out other probable causes for the
symptoms [20]. For the moment, early diagnosis is based on
the early recognition of the various signs and symptoms, as
the most common sign of the disease is memory loss, es-
pecially forgetting recently learned information.
Generally, a timely and accurate diagnosis is considered
to be important, as treatment of Alzheimer’s and other
dementia-causing diseases is typically most eﬀective when
started early in the disease process [21, 22]. Additionally,
accurate diagnosis could transform the design and execution
of clinical trials to test new AD treatments [23–27].
Current diagnosis methods mainly rely either on sub-
jective tests or invasive methods with a limited accuracy.
Deﬁnite AD diagnosis is possible only through postmortem
observation of the aberrant accumulation of β-amyloid
peptides (Aβ) extracellular aggregates, β-amyloid plaques,
and protein tau intracellular twisted strands (neuroﬁbrillary
tangles, NFTs) [26–31]. *e inaccuracy of the existing di-
agnostic methods, limits the general applicability for vast
population screening and underlines the need for the
identiﬁcation of easily accessible tools for the identiﬁcation
of high-risk subjects. To better serve the population at risk of
developing AD, new methods of deﬁnitive, noninvasive and
lower cost diagnosis are needed.
AD could be categorized in familial Alzheimer’s disease
(FAD, also known as early-onset Alzheimer’s disease) and
sporadic type (also known as late onset Alzheimer’s disease;
LOAD) [32]. *e eye oﬀers a natural window to the brain as
the retina, the light-sensitive layer lining the interior of the
eye is considered part of the central nervous system (CNS)
and the only optically accessible nervous tissue [33]. Neu-
rodegenerative changes in the brain produced by AD are
accompanied by structural and possible functional changes
in the neuroretina and the ocular vasculature.
Numerous recent studies reported the presence of
β-amyloid plaques in the retina of patients, opening the
possibility of detecting AD though simple noninvasive eye
scans [34–38]. In a parallel way, other studies revealed
degenerative changes and retinal neuron damage in the
retina/eye of AD animal models [39–43]. Consequently,
various laboratories are trying to explore this approach,
developing optical retinal imaging platforms capable to
detect β-amyloid plaques in the retina of AD subjects
[38, 44–48]. *ese novel imaging platforms are expected to
early detect the presence of AD hallmarks and assist in
monitoring the eﬃcacy of probable future therapeutic agents
which target relevant molecular pathways.
Nevertheless, Alzheimer’s disease shares common
features, mode-of-action, and targets with other neurode-
generative diseases such as, Parkinson’s disease, Hunting-
ton’s disease, amyotrophic lateral sclerosis, frontotemporal
dementia, and even glaucoma and macular degeneration
[49–52]. *erefore, in the following text, we will analyse
the relation between AD and some of these neurodegen-
erative disorders, focusing on their ocular manifestations
on the accessible retina, and the possibility of using these
hallmark signs as structural-functional biomarkers for risk
assessment-monitoring of disease progression, and evalua-
tion for the drug therapeutic eﬃcacy. In any case, the es-
tablishment of a link between neurodegenerative diseases
and ocular manifestations is an interesting emerging ﬁeld of
study.
2. Detection and Pathophysiological Processes
Involved in Alzheimer’s Diseases and Other
Neurodegenerative Diseases
Several studies have focused upon the relationship between
neurodegenerative diseases and their possible ocular man-
ifestation. *ere is compelling evidence to suggest that
speciﬁc ocular biomarkers related to neurodegenerative
disorders play a pivotal role in the development of retinal
impairment or loss of visual function [53, 54].
*e abnormal protein aggregation characterizes nu-
merous neurodegenerative diseases, where insoluble pro-
teins are accumulated in the brain such as AD, the Prion
Encephalopathies, Parkinson´s disease, Huntington dis-
ease, and other polyglutamine disorders [55]. Protein
misfolding diseases are not exclusive to the CNS, including
disorders implicating amyloidogenic proteins like type 2
diabetes, inherited cataracts, vascular inﬂammation, ath-
erosclerosis, and haemodialysis-related disorders, among
many others [56]. Goldstein et al. reported the detection of
nanoaggregates of β-amyloid in the human AD lens [57],
a non-CNS structure considering another relevant ocular
hallmark in this pathology. Deposits of β-amyloid are
a distinct characteristic found in neurodegenerative dis-
eases AD [58–60], Parkinson’s disease [60–65], as well as
being detected in age-related macular degeneration [66],
and glaucoma [67–70].
In fact, there are numerous recent studies connecting
glaucoma and AD, and some, bearing in mind the multiple
common features to both diseases, including risk factors
and pathophysiological mechanisms, are suggesting that
Alzheimer’s Disease and glaucoma should be considered
age-related neurodegenerative diseases, coexisting in the
elderly population [71–74]. Adding to the connection link
theories between glaucoma and AD is the recent unifying
hypothesis of the “glymphatic system.” *is hypothesis is
incorporating various aspects of the vascular, bio-
mechanical, and biochemical theories, based on a few
studies suggesting the existence of a paravascular transport
system in the eye and optic nerve. However, for the mo-
ment, there are not suﬃcient available research data to
totally support this idea [75–78].
On the other hand, recent studies are suggesting that AD
and age-related macular degeneration (AMD) share com-
mon, pathological signalling defects and disease mecha-
nisms at the molecular genetic level [79, 80]. *ere is
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growing evidence that β-amyloid, the main component of
senile plaques, the hallmark of AD, is also a vital component
of drusen, the hallmark of AMD [81–83]. While AMD is
a retinal disease, AD is damaging the brain cells as well as the
retina. *ese two age-related diseases are primarily aﬀecting
distinct parts of the central nervous system but are generally
similar, concerning the abnormal extracellular deposits,
metabolic and oxidative stress, neuroinﬂammation, and
microvascular abnormalities [81, 84].
AD is characterized by visual disturbances at early
stages which are correlated to neuronal damage in the inner
retina, loss of RGCs, and optic nerve degeneration at
postmortem histology, as suggested by several authors
[37, 38, 85–91] and is also correlated to Parkinson’s disease,
as suggested by Bayer et al. [92]. Further studies reported
that these inner retinal alterations were correlated with an
abnormal pattern electroretinography (pERG) response
[93]. From the earliest stages of the disease, amyloid plaque
is deposited in retina tissue (including the RGC, retinal
nerve ﬁbre layer-RNFL, and inner plexiform layer) which
can produce a ﬂuorescence eﬀect by using curcumin as
a contrast [94].
An important characteristic of many systemic processes
related to AD is the contribution of the energy metabolism,
albeit the role of altered metabolic processes implicated in
Alzheimer’s disease pathogenesis is still unclear [95]. Recent
studies discovered that in several CNS disorders, there is
evidence of circulating metabolites signatures, suggesting
that retinal oxygen metabolism in AD is slightly diﬀerent
from the normal, even though the results are not conclusive
(ClinicalTrials.gov Identiﬁer: NCT02253732; ClinicalTrials.
gov Identiﬁer: NCT00001972) [96, 97]. Following this dis-
covery, the University of Iceland, Reykjavı´k, Iceland, is
developing a biomarker for AD albeit further studies are
necessary, using larger groups, to verify the results and
further metabolomic studies and are imperative to dem-
onstrate the correlation between systemic abnormalities and
the brain impairment in AD [60].
*e Spanish Hospital Universitari Vall d’Hebron Re-
search Institute is investigating the association between type
2 diabetes (T2D) and Alzheimer’s disease (AD) [98, 99] and
in September 2014, started a clinical trial (ClinicalTrials.gov
Identiﬁer: NCT02360527) to explore whether diabetic pa-
tients are at risk of developing AD based on the assessment
of retinal neurodegeneration and if these retina irregularities
are related to the severity of AD. *e results suggest that
retinal sensitivity, assessed by microperimetry, is related to
brain neurodegeneration and could be a useful biomarker
for the detection of the disease [100].
In the University Hospital of Bordeaux, scientists are
studying how the reduced thickness of RNFL relates to AD
and other degenerative diseases and if RNFL thickness is
associated with the development of cognitive impairment.
*ey suggest that this parameter could be used as a bio-
marker for cerebral axonal degeneration, as RNFL deﬁcits
could be an early sign of AD, even before damages occur in
the hippocampal region (ClinicalTrials.gov Identiﬁer:
NCT01621841- ClinicalTrials.gov Identiﬁer: NCT01555827)
[101–104]. *e results conﬁrm that the RNFL thickness is
associated with changes in patients’ memory and could be
used as an indicator for the future development of AD [104].
In another instance, in the Department of Neurosurgery
and Maxine Dunitz Neurosurgical Research Institute,
Cedars-Sinai Medical Centre, Los Angeles, trials have begun
to administrate intravenous therapy of curcumin, a ﬂuo-
rophore with high aﬃnity to Aβ, to an AD-Tg mice (n � 24)
mouse model and performed ﬂuorescent retinal examina-
tion in vivo [34]. After systemic administration of curcumin
using this method, noninvasive optical imaging of retinal
β-amyloid plaques in vivo with high resolution and speci-
ﬁcity was allowed [105]. Curcumin is used as an early di-
agnostic probe due to its inherited ﬂuorescence and high
binding aﬃnity to amyloid-β, but it could also be the basis of
new drugs for the prevention and treatment of AD [106].
In 2011, Koronyo-Hamaoui and colleagues described the
presence of β-amyloid in human retinal whole mount of AD.
Posterior studies showed the predominant superior hemi-
retina damage involving mainly the inner retinal layers and
histological analysis provided evidence of increased AβPP in
AD retinas [5, 34, 49, 107]. In addition, speciﬁc retinal
ganglion cells (RGC) and melanopsin retinal ganglion cells
(mRGC) are aﬀected by amyloid pathology in AD in and
around cells [37].
Numerous studies of transgenic rodent models of AD
have identiﬁed retinal Aβ depositions in the inner retina
(inner plexiform layer, RGC layer, and nerve ﬁbre layers)
and the outer nuclear layer. *ese ﬁndings correlate with the
burden of amyloid plaques in the brain [34, 38, 107–109].
Furthermore, the pathological mechanisms that involve
β-amyloid in neuronal death are similar between RGC loss
and neuronal degeneration in hippocampus in diﬀerent
models of AD [66, 85–90, 110]. RGC apoptosis was ac-
companied by and localized with Aβ deposits in retinas
from rodent models, and signalling pathways are similar
in retinal and hippocampal neurons death [107, 111]. Based
on the observation on the retina of β-amyloid plaques,
various companies and research centres started the devel-
opment of speciﬁc biomarkers for the AD early diagnosis.
In December 4, 2017 the Canadian company Optina Di-
agnostics Inc. started the ClinicalTrials.gov Identiﬁer:
NCT03420807 for the evaluation of a device called metabolic
hyperspectral retinal camera (MHRC) for the detection of
β-amyloid plaques. A hyperspectral mydriatic camera is
used, producing multiple images of the retina, collecting
and processing the light intensity for a large number (225) of
contiguous spectral bands at high speeds allowing the
noninvasive localization of structures and biomolecules in
the retina evaluating their speciﬁc spectral signatures
[112–114]. *is method is based on the β-amyloid plaques
hypothesis of AD pathophysiology, even though it generally
remains unproven by clinical interventions [115].
Other studies support the hyperspectral imaging mi-
croscopy (HSI) method, to examine Aβ presence without the
need for exogenous ﬂuorophore. More and colleagues
demonstrated the spectral signature of aggregated Aβ in AD
mice model retinas and in vivo detection [116, 117].
While the optical examination sector appears extremely
interesting for the development of a novel noninvasive
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diagnostic tool, for the moment, research has barely sur-
passed the animal model level, and there is limited proof yet
that it is possible to detect β-amyloid plaques in the retina by
visual means.
In addition to growing reports of retinal Aβ accumu-
lation, other established hallmark of AD is pTau protein
aggregates. Alterations in tau protein and gene expression
were found in a triple transgenic mouse model revealing
neuronal dysfunction that precedes cell death in the AD
retina. In addition, these results were correlated to the
presence of tau accumulation in the RGC soma and den-
drites [38, 41, 118, 119]. Hyperphosphorylated tau was
detected in postmortem human retinas and in AD animal
models, which led us to the hypothesis that this could be
observed at a presymptomatic stage of the disease as tau
aggregation was not detected [118, 120, 121].
AD is a progressive brain disorder, with strong genetic
determinants and aggregated protein, responsible for de-
mentia. For many decades, the main environmental factors
that inﬂuence the risk of AD development have been
thoroughly studied. *e primary risk factors involve hy-
pertension, diabetes, hyperlipidaemia, metabolic syndrome,
unhealthy diet, smoking, and physical inactivity among
others [1, 122, 123]. It is considered that all these factors may
contribute to the dilapidated physiopathological mecha-
nisms in AD development.
Detection of speciﬁc biomarkers or advanced AD di-
agnosis approaches in the preclinical stage would be a po-
tential breakthrough in the management of AD. Recent
studies suggest that the retinal alterations occur early,
thereby suggesting the necessity of earlier diagnosis and
subsequent treatment of AD. Retinal imaging could, there-
fore, serve as an alternative approach to assessing brain
degeneration in AD. Over the last 15 years, a noninvasive
optical imaging technique of the retina and OHN has been
used as a valuable tool to assess the optic nerve pathology in
AD. In vivo detection of amyloid deposits in AD retinas were
reported using OCT, and ﬁndings included perimacular and
perivascular spots in the outer plexiform layer (OPL),
ganglion cell layer (GCL), and the nerve ﬁbre layer (NFL)
thinning in AD [124–127].
In the Commonwealth Scientiﬁc and Industrial Research
Organisation (CSIRO), Perth, WA, Australia, scientists
began a study of AD patients, to discover whether the
vascular analysis of retinal photographs could identify any
retinal vascular parameters (RVPs) and when these retinal
changes occur. *e study demonstrated that retinal vascular
biomarker is a potential method for the early detection of
AD [128]. Likewise, researchers in Duke University of
London developed a diagnostic method based on retinal
imaging. In July 2017, a clinical trial with reference
ClinicalTrials.gov Identiﬁer: NCT03233646 was undertaken
to evaluate a noninvasive OCTA-based retinal microvas-
cular biomarker, as an eﬀective screening tool in cognitive
aging. *e investigators hypothesize that microvascular
network alterations in the retinamirror and possibly precede
changes in the cerebral microcirculation seen in AD. Using
advanced image analysis, the investigators aim to evaluate
markers of reduced capillary blood ﬂow and nonperfusion in
the superﬁcial and deep retinal vascular plexuses and cho-
riocapillaris imaging using OCTA that would complement
already established retinal-structural markers and increase
their sensitivity and speciﬁcity in the early detection of AD.
Various studies found that patients with AD have less
density of retinal microvascular networks than the normal,
considering retinal vessel reaction to ﬂicker stimulation as
a promising noninvasive, widely available, and easy-to-
administer future biomarker for the diagnosis and moni-
toring of AD [129, 130]. In another study, the OCTA tech-
nique was tested on patients with AD, demonstrating its
eﬃcacy as a biomarker in the early diagnosis of the disease
[131]. Additionally, the Medical University of Vienna is in-
vestigating whether more functional changes can be detected
in the retina of AD patients, in conjunction with the already
identiﬁed aberrations. For this purpose, in September 2016,
they began a clinical trial (ClinicalTrials.gov Identiﬁer:
NCT02663531) evaluating the relationship between neural
activity and blood ﬂow, in induced ﬂicker light hyperaemia in
the retina, as a possible biomarker for AD. Furthermore, they
assessed structural parameters such as retinal nerve ﬁbre layer
thickness and function parameters such as ocular blood ﬂow
and retinal oxygenation [132, 133]. According to the results,
neuritic plaques were detected in representative cortical re-
gions, suggesting OCTA as a useful tool for three-dimensional
imaging of retinal Aβ accumulation [134, 135].
In general, advances in the image processing and soft-
ware have improved the interpreting of anterior segment
OCT images. In any case, the technique must advance to-
wards the reﬁnement of assessing vascular networks for the
anterior segment and improvement of the histology detail, to
become more accurate and to facilitate its use.
Studying the retinal visual changes of patients with
neurodegeneration is an emerging ﬁeld that requires more
investigation. Intraocular and systemic therapeutic
biomarkers/agents and visualizing techniques may be de-
veloped, serving the dual purposes of establishing novel
pharmacological targets and new technological sources.
*e mentioned areas of research have come a long way
with many and important results, allowing us to have
a better understanding of the disease [47]. More eﬀorts are
still needed, however, to fully understand the aetiology of the
disease, to establish reliable individual predictive models,
and place us closer to the development of a deﬁnitive di-
agnostic method and a possible personalized treatment.
3. Ophthalmological and Ocular
Clinical Symptoms
*e ocular alterations in AD involve diﬀerent structures in
the anterior and posterior pole (Table 1). In the anterior pole,
tear ﬂuid is considered to be a potential biomarker source.
Kallo et al. discovered 100% increase of ﬂow rate and 100%
increase in protein levels in AD patients, with respect to the
age-matched controls.*e combination of four tear proteins
lipocalin-1, dermicidin, lysozyme C and lactritin, had 81%
sensitivity and 77% speciﬁcity for AD [136]. Furthermore,
abnormal tear functions and reduced corneal sensibility
were described in previous studies of neurodegenerative
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diseases [137]. In 2017, the French company Amoneta Di-
agnostics SAS started a clinical trial (ClinicalTrials.gov Identi-
ﬁer: NCT03030586) to validate the performance of
a noninvasive peripheral blood diagnostic kit for AD, collecting
samples from peripheral body ﬂuids, tears being among them.
Pupillary responses are associated with brain impair-
ment in diﬀerent studies where light reﬂex amplitude is
reduced in AD [177]. Granholm et al. suggest that task-
evoked pupillary responses may be a psychophysiological
biomarker of early risk for AD [158]. *e Massachusetts
General Hospital started a clinical trial (ClinicalTrials.gov
Identiﬁer: NCT03330353) in 2017 to investigate rod, cone,
and melanopsin-driven pupillary light response in in-
dividuals, as a possible AD and other neurodegenerative
diseases diagnostic method. Furthermore, the Centre Hos-
pitalier Universitaire de Besancon France recently began
a clinical trial (ClinicalTrials.gov Identiﬁer: NCT01434940)
to validate eye movement recording as an early diﬀerential
diagnostic tool for AD. Tracking eye movements is be-
coming an interesting diagnostic technique and could be
beneﬁcial in recognizing individuals who will progress to
AD, but for the moment, there remain many critical points
which require additional investigation.
As previously commented, β-amyloid was detected in the
human lens of ADpatients, and in a FraminghamOﬀspring Eye
Study cohort, a correlation between cortical cataract and AD
degeneration was observed [124, 156, 178, 179]. *ese ﬁndings
establish the β-amyloid protein as a key pathogenic biomarker
between lens and AD. In 2017, the American company
Cognoptix, Inc. started a clinical trial to detect β-amyloid in the
lens of the eye in patients with mild cognitive impairment
(MCI), and mild AD after the instillation of Aftobetin Hy-
drochloride. Aftobetin, also known as ANCA11 andNCE-11, is
an amyloid-binding compound applied topically in the form of
an ophthalmic ointment and may be useful as an aid in the
diagnosis of AD (ClinicalTrials.gov Identiﬁer: NCT02928211).
Finally, in another ocular ﬂuid, the aqueous humour;
higher levels of proteins involved in AD pathology such as
β-amyloid peptides; and a series of chemokines, including
eotaxin, eotaxin 3, and interleukin [IL]-8 (160) were detected in
cataract surgery patients. Additionally, Inoue et al. suggest that
open-angle glaucoma patients presented elevated levels of
various biomarkers of AD in the aqueous humour, including
apolipoprotein (Apo) AI, ApoCIII, ApoE, transthyretin (TTR),
complement factor H, complement C3, and α2-macroglobulin
(α2M) [162].
Table 1: Visual system pathological and functional alterations in Alzheimer’s disease.
Ocular structures and clinical facts Pathological changes
Retina
Deposition of proteins tau, Aβ, and pTAu [35, 38, 39, 118]; accumulation of phosphorylated
tau protein [138, 139]
Impairment of amyloid β precursor protein (APP) metabolism [140, 141, 142]
Reduction in retinal ganglion cells (RGCs) [85–87,143]
Reduction of retinal thickness [85, 93, 144]
Reduction to the retinal nerve ﬁbre layer (RNFL) thickness [89, 145]
Retrograde degeneration from loss of cortical neurons [146, 147]
Inﬂammation [148, 149, 150]
Retinal and choroidal vasculature
Retinal and choroidal vascular β-amyloid deposits in transgenic mouse model of AD lead to
retinal degeneration [107]
Reduction of vascularization [151]
Retinal vascular blood ﬂow Blood ﬂow abnormalities may cause neurodegeneration [152]
Optic nerve
Axonal degeneration in the axonal segments [85, 140]
Loss of optic nerve thickness [153, 154]
Papillary paleness due to axonal loss and perfusion alterations [155]
Lens Correlation between AD and supranuclear cataract [156, 157]Presence of abnormal protein deposits [124, 157]
Tears Changes in the chemical barrier composition of tears [136]
Cornea Reduced corneal sensitivity [137]
Pupil Pupillary responses possible biomarker [158, 159]
Choroid Attenuation of choroidal thickness [160, 161]
Aqueous humour Detection of Alzheimer connected, β-amyloid peptides, and chemokines in the aqueoushumour [162, 163]
Visual ﬁeld Dysfunction in diﬀerent tasks of basic vision and visual cognition [164]
Visual acuity Decreased visual acuity [165]
Sensory perception Clinically important symptoms of visuospatial disorientation [166, 167]
Visual processing Deﬁcits of visual motion perception [168]
Contrast sensitivity Contrast sensitivity disturbances and motion perception [169, 170]
Colour vision Incomplete achromatopsia [171]
Stereopsis Reduced stereoscopic depth perception [172, 173]
Circadian rhythm Alterations in the circadian rhythm and β-amyloid deposits inside and surroundingdegenerating mRGCs [174–176]
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In the posterior pole, retinal thickness is correlated to
cortical atrophy and choroid and NFL is thinning in AD
patients [85, 93, 144, 145, 153, 155, 160]. Several reports in
AD patients, showed RGC loss [85, 86, 143]. Additionally,
studies in patients and on AD animal models displayed Aβ
and tau proteins accumulation in inner retinal layers
[138, 143, 180]. Furthermore, Rusu et al. detected APP
metabolism impairment in transgenic drosophila [140] and
Paris et al. detected a reduction of angiogenesis processes in
transgenic mice [151]. In addition, studies on patients and
animal models reveal that activated microglia and proin-
ﬂammatory molecules are contributing to the development
of the pathology, and they are degenerating neurons, de-
creasing retinal activity [111, 148, 149, 181].
All these morphological and/or biochemical changes are
leading to decreased visual acuity, deﬁcits in visual per-
ception, anomalies of colour vision, visual cognition im-
pairment, and visuospatial disorientation. In summary, all
these ﬁndings are creating the certainty that visual abnor-
malities of the visual axis, from RGC to visual cortex, are
common ocular characteristic features of AD [164–166, 168].
4. Conclusions
AD diagnosis is based on the interpretation of the signs and
symptoms of the disease in cerebrospinal ﬂuid (CSF) tests
and neuroimaging of the brain. Recent major advances in
brain imaging are providing opportunities for a more ac-
curate diagnosis, but unfortunately, this technique has
limited availability, and its costs are high, making
population-wide screening challenging. Consequently, there
is a global need for novel early diagnostic methods, more
speciﬁc, more economic, and with the added ability to
distinguish AD among the diverse types of neurodegener-
ative disorders, bearing in mind that AD diagnosis must
identify the disease before the cognitive deﬁcits have reached
the threshold of dementia.
*e eye shares many neural and vascular similarities
with the brain, directing many researchers towards the
discovery and development of novel ocular biomarkers,
which could have a profound inﬂuence on early diagnosis
and the discovery of new treatments for the disease.
Numerous recent studies reported the presence of
β-amyloid plaques, the hallmark of the disease, in the retina
of AD mice models and humans, opening the possibility of
detecting AD through a simple noninvasive eye scan.
Various laboratories are exploring this approach with the
development of optical retinal imaging platforms to detect
β-amyloid plaques in the retina of AD subjects. *ese novel
imaging platforms are expected to help aid the early de-
tection of AD and assist in monitoring the eﬃcacy of
probable future therapeutic agents which target relevant
molecular pathways.
Another imminent change concerning the diagnosis of
the neurodegenerative diseases through the eye would be the
greater role of the primary eye care practitioners in a sector
that previously had little implication.
While a considerable number of clinical trials are cur-
rently underway to evaluate novel diagnostic methods,
through the eye, and the results are promising, for the
moment, the biomarkers for the diagnosis of Alzheimer’s
disease (AD) are not yet validated for use in clinical settings,
and their widespread implementation remains a challenge.
Among the reasons for this, we could underline the lack of
experience of the researchers to interpret the huge data
obtained from these eye images, ethnic variation causing
further complications, the overlap with other diseases, and
the lack of speciﬁcity of these biomarkers. In general, there is
a need for a greater number of validation studies involving
wider cohorts of various ethnicities and origins. Another
question arising in the use of eye biomarkers is that perhaps
they are too late as by the time β-amiloide plaques are
discovered in the retina, the disease has already progressed.
Finally, the cascade of events resulting in retinal cell
death in ocular neurodegenerative pathologies is leading
scientists to a new common descriptive term of diseases of
the retina. Even though the aetiology of AMD, glaucoma,
and AD is still uncertain, studying the common features
between them may provide further knowledge about their
pathogenesis and could lead to accelerated development of
therapies for both diseases. Additionally, studying AD-
related retinal degeneration is a promising way forward in
the investigation of AD pathologies and therapies, which
could eventually beneﬁt the brain and cellular mechanisms
in other retinal degenerations.
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